Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity

Corresponding Author

Ebtehal El-Demerdash

Pharmacology & Toxicology Department, Faculty of Pharmacy, Ain Shams University

Ebtehal El-Demerdash, Department of Pharmacology & Toxicology, Faculty of Pharmacy, Ain Shams University, Abasia, Cairo, Egypt. E-mail: [email protected]Search for more papers by this author

Azza A. Ali,

Azza A. Ali

Pharmacology & Toxicology Department, Faculty of Pharmacy, Al-Azhar University

Search for more papers by this author

Dalia E.M. El-Taher,

Dalia E.M. El-Taher

Hospitals of Ain Shams University, Cairo, Egypt

Search for more papers by this author

Farid M.A. Hamada,

Farid M.A. Hamada

Pharmacology & Toxicology Department, Faculty of Pharmacy, Al-Azhar University

Search for more papers by this author

Ebtehal El-Demerdash,

Corresponding Author

Ebtehal El-Demerdash

Pharmacology & Toxicology Department, Faculty of Pharmacy, Ain Shams University

Ebtehal El-Demerdash, Department of Pharmacology & Toxicology, Faculty of Pharmacy, Ain Shams University, Abasia, Cairo, Egypt. E-mail: [email protected]Search for more papers by this author

Azza A. Ali,

Azza A. Ali

Pharmacology & Toxicology Department, Faculty of Pharmacy, Al-Azhar University

Search for more papers by this author

Dalia E.M. El-Taher,

Dalia E.M. El-Taher

Hospitals of Ain Shams University, Cairo, Egypt

Search for more papers by this author

Farid M.A. Hamada,

Farid M.A. Hamada

Pharmacology & Toxicology Department, Faculty of Pharmacy, Al-Azhar University

Search for more papers by this author

First published: 07 December 2011

https://doi.org/10.1111/j.2042-7158.2011.01413.x

Citations: 13

Share a link

Email
Wechat
Bluesky

Abstract

Objectives Anthracyclines are broad spectrum anticancer drugs with dose-dependent cardiotoxicity. Protein malnutrition commonly occurs in cancer patients and is considered a risk factor for development of cardiotoxicity. This study was designed to assess the modulatory effect of protein malnutrition on the pharmacokinetics and drug disposition properties of a single dose of doxorubicin and epirubicin and how these possible changes will affect the degree of cardiotoxicity of these drugs.

Methods A single interperitoneal dose of 15 mg/kg of either doxorubicin or epirubicin was injected into rats fed with either normal protein diet or low-protein diet. The plasma concentration–time profiles of doxorubicin and epirubicin and their concentrations in different tissues were determined. Serum creatine kinase level was determined at different time intervals and histopathological examination of heart tissue was carried out.

Key findings Protein malnutrition significantly altered the pharmacokinetics of doxorubicin and epirubicin, with a significant decrease in their elimination, and prolonged the exposure of the heart to these drugs. Histopathological examination and serum creatine kinase measurements supported the role of protein malnutrition in enhancement of anthracycline cardiotoxicity.

Conclusions If similar alteration in anthracyclines' pharmacokinetics occurs in malnourished cancer patients, protein malnutrition will be a risk factor for development of anthracycline cardiotoxicity and dose adjustment will be required in nutritionally deprived patients.

References

1 Baron RB. Malnutrition in hospitalized patients – diagnosis and treatment. West J Med 1986; 144: 63–67.
PubMed Web of Science® Google Scholar
2 Fearon KCH. The mechanisms and treatment of weight loss in cancer. Proc Nut Soc 1992; 51: 251–265.
10.1079/PNS19920036
CAS PubMed Web of Science® Google Scholar
3 Elia M et al. Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer. Eur J Oncol Nurs 2005; 9: S39–S50.
PubMed Google Scholar
4 Laviano A, Meguid MM. Nutritional issues in cancer management. Nutrition 1996; 12: 358–371.
10.1016/S0899-9007(96)80061-X
CAS PubMed Web of Science® Google Scholar
5 Bozzetti F. Nutrition support in patients with cancer. In: J Payne-James et al., ed. Artificial Nutrition Support in Clinical Practice, 2nd edn. London: GMM, 2001: 639–680.
Google Scholar
6 Argile's JM. Cancer-associated malnutrition. Eur J Oncol Nurs 2005; 9: S39–S50.
10.1016/j.ejon.2005.09.006
PubMed Google Scholar
7 Armes PJ et al. A study to investigate the incidence of early satiety in patients with advanced cancer. Br J Cancer 1992; 65: 81–484.
10.1038/bjc.1992.98
Web of Science® Google Scholar
8 Andreyev HJN et al. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998; 34: 503–509.
10.1016/S0959-8049(97)10090-9
CAS PubMed Web of Science® Google Scholar
9 Lee JH et al. Pharmacokinetic changes in drugs during protein-calorie malnutrition: correlation between drug metabolism and hepatic microsomal cytochrome P450 isozymes. Arch Pharm Res 2004; 27: 693–712.
10.1007/BF02980136
CAS PubMed Web of Science® Google Scholar
10 Danesi R et al. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. Br J Clin Pharmacol 2002; 53: 508–518.
10.1046/j.1365-2125.2002.01579.x
CAS PubMed Web of Science® Google Scholar
11 Bachur NR et al. Helicase inhibition by anthracycline anticancer agents. Mol Pharmacol 1992; 41: 993–998.
CAS PubMed Web of Science® Google Scholar
12 Camaggi CM et al. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. Cancer Chemother Pharmacol 1988; 21: 221–228.
10.1007/BF00262774
CAS PubMed Web of Science® Google Scholar
13 Robert J. Epirubicin: clinical pharmacology and dose-effect relationship. Drugs 1993; 45: 20–30.
10.2165/00003495-199300452-00005
PubMed Google Scholar
14 Yoshida H et al. Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis. Cancer Chemother Pharmacol 1994; 33: 450–454.
10.1007/BF00686499
CAS PubMed Web of Science® Google Scholar
15 Ricciarello R et al. Simultaneous determination of epirubicin, doxorubicin and their principal metabolites in human plasma by high performance liquid chromatography and electrochemical detection. J Chromatogr B 1998; 707: 219–225.
10.1016/S0378-4347(97)00610-5
CAS PubMed Web of Science® Google Scholar
16 Outomuro D et al. Adriamycin-induced myocardial toxicity: new solutions for an old problem. Int J Cardiol 2007; 117: 6–15.
10.1016/j.ijcard.2006.05.005
PubMed Web of Science® Google Scholar
17 Kim SB et al. Role of hypoalbuminemia in the genesis of cardiovascular disease in dialysis patients. Perit Dial Int 1999; 19: 144–149.
PubMed Web of Science® Google Scholar
18 Hiroe M et al. Myocardial uptake of 111 in monoclonal antimyosin Fab in detecting doxorubicin cardiotoxicity in rats: morphological and hemodynamic findings. Circulation 1992; 86: 1965–1972.
10.1161/01.CIR.86.6.1965
CAS PubMed Web of Science® Google Scholar
19 Oumi M et al. The ultrastructure of skeletal and smooth muscle in experimental protein malnutrition in rats fed a low protein diet. Arch Histol Cytol 2000; 63: 451- 457.
10.1679/aohc.63.451
CAS PubMed Web of Science® Google Scholar
20 Norlen P et al. Anaesthetic agents inhibit gastrin-stimulated but not basal histamine release from rat stomach ECL cells. Br J Pharmacol 2000; 130: 725–730.
10.1038/sj.bjp.0703347
CAS PubMed Web of Science® Google Scholar
21 Formelli F et al. Fluorescence assays and pharmacokinetic studies of 4'deoxydoxorubicin and doxorubicin in organs of mice bearing solid tumors. Cancer Chemother Pharmacol 1981; 5: 139–144.
10.1007/BF00258470
CAS PubMed Web of Science® Google Scholar
22 Rhaman M et al. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res 1986; 46: 2295 – 2299.
PubMed Web of Science® Google Scholar
23 Szasz G et al. Creatine kinase in serum: interference of adenylate kinase with the assay. Clin Chem 1975; 22: 1806 – 1811.
PubMed Web of Science® Google Scholar
24 Vora J, Boroujerdi M. Pharmacokinetic-toxicodynamic relationship of adriamycin in rat: prediction of butylate dhydroxyanisole- mediated reduction in anthracycline cardiotoxicity. J Pharm Pharmacol 1996; 48: 1264–1269.
10.1111/j.2042-7158.1996.tb03934.x
CAS PubMed Web of Science® Google Scholar
25 Oumi M et al. Ultrastructural changes and glutathione depletion in the skeletal muscle induced by protein malnutrition. Ultrastruct Pathol 2001; 25: 431– 436.
10.1080/019131201753343467
CAS PubMed Web of Science® Google Scholar
26 Kim YG et al. Effects of cysteine on the pharmacokinetics and pharmacodynamics of intravenous and oral azosemide in rats with protein-calorie malnutrition. Life Sci 2001; 68: 2329–2345.
10.1016/S0024-3205(01)01025-6
CAS PubMed Web of Science® Google Scholar
27 Lima Y et al. Dietary supplementation of N-acetylcysteine enhances early inflammatory responses during cutaneous wound healing in protein malnourished mice. J Nutr Biochem 2006; 17: 328– 336.
10.1016/j.jnutbio.2005.08.004
CAS PubMed Web of Science® Google Scholar
28 Cusack BJ et al. Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. Cancer Chemother Pharmacol 1992; 30: 145–148.
10.1007/BF00686407
CAS PubMed Web of Science® Google Scholar
29 Kim YG et al. Effects of cysteine on the pharmacokinetics of intravenous adriamycin in rats with protein-calorie malnutrition. Res Commun Mol Pathol Pharmacol 2000; 107: 361–376.
CAS PubMed Web of Science® Google Scholar
30 Ramanathan-Girish S, Boroujerdi M. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics, and toxicodynamics after single- and multiple- dosing in rats. J Pharm Pharmacol 2001; 53: 987–997.
10.1211/0022357011776234
CAS PubMed Web of Science® Google Scholar
31 Ramírez de Martens LM et al. Protein-energy malnutrition and hypobaric stress effects on ultrastructure of the heart muscle in rats. Acta Cient Venez 1998; 49: 31–37.
PubMed Google Scholar
32 Zhou S et al. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 2001; 61: 771–777.
CAS PubMed Web of Science® Google Scholar
33 Andreadou I et al. Acute doxorubicin cardiotoxicity is successfully treated with the phytochemic aloleuropein through suppression of oxidative and nitrosative stress. J Mol Cell Cardiol 2007; 42: 549–558.
10.1016/j.yjmcc.2006.11.016
CAS PubMed Web of Science® Google Scholar
34 Kaklamani VG, Gradishar WJ. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer 2003; 4 (Suppl. 1): S26–S33.
10.3816/CBC.2003.s.012
PubMed Google Scholar

Citing Literature

Volume64, Issue3

March 2012

Pages 344-352

Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity

Abstract

References

Citing Literature

References

Related

Information